Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study

Abstract Background Serious bleeding events have been frequently described in patients taking direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma concentrations were shown to correlate with bleeding outcomes. This study aimed to describe rivaroxaban plasma levels...

Full description

Bibliographic Details
Main Authors: Anne-Laure Sennesael, Anne-Sophie Larock, Jonathan Douxfils, Laure Elens, Gabriel Stillemans, Martin Wiesen, Max Taubert, Jean-Michel Dogné, Anne Spinewine, François Mullier
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Thrombosis Journal
Subjects:
Direct oral anticoagulants
Rivaroxaban
Bleeding
Drug monitoring
Pharmacogenomics
Patient safety
Online Access:http://link.springer.com/article/10.1186/s12959-018-0183-3

Internet

http://link.springer.com/article/10.1186/s12959-018-0183-3

Similar Items